Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8206269 | 0.90 | ADRB2 (0.45) | KLKB1KLK1ADRB2ROCK2ROCK1 | |
| SCHEMBL8213781 | 0.89 | ADRB2 (0.47) | KLKB1KLK1ADRB2ROCK2ROCK1 | |
| SCHEMBL8209302 | 0.87 | ADRB2 (0.41) | KLKB1KLK1ADRB2ROCK2ROCK1 | |
| SCHEMBL8206379 | 0.87 | KLKB1 (0.40) | IRAK4KLKB1KLK1ADRB2ROCK2 | |
| SCHEMBL8206294 | 0.87 | ADRB2 (0.46) | KLKB1KLK1ADRB2ROCK2ROCK1 | |
| SCHEMBL12853326 | 0.86 | ADRB2 (0.39) | KLKB1KLK1ADRB2ROCK2ROCK1 | |
| SCHEMBL12853298 | 0.85 | ADRB2 (0.44) | KLKB1KLK1ADRB2ROCK2ROCK1 | |
| SCHEMBL12853327 | 0.85 | ROCK2 (0.47) | KLKB1KLK1ADRB2ROCK2ROCK1 | |
| SCHEMBL12853254 | 0.85 | HPGD (0.44) | KLKB1KLK1ADRB2CA1CA2 | |
| SCHEMBL8201431 | 0.84 | KLKB1 (0.50) | KLKB1KLK1ADRB2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278337-B2 | Substituted pyridines that are JNK inhibitors | MERCK SHARP & DOHME (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179141-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-07-15 | — | — | US | disclosed |
| WO-2008082487-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179141-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK5, MAPK15 | IRAK4 429/4885KLKB1 1959/4885KLK1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.